Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide

Journal of Cardiovascular Magnetic Resonance

Volumn 17, Issue 1, 2015, Pages

  Alam, Shirjel R ^a,b   Stirrat, Colin ^a,b   Richards, Jennifer ^a   Mirsadraee, Saeed ^b,c   Semple, Scott I K ^c   Tse, George ^d   Henriksen, Peter ^a,b   Newby, David E ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cardiovascular imaging; CMR; Inflammation; Macrophage; Nanoparticles; USPIO

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; DEXTRAN; FERUMOXTRAN-10; MAGNETITE NANOPARTICLE;

ABDOMINAL AORTA ANEURYSM; CARDIOVASCULAR MAGNETIC RESONANCE; CAROTID ATHEROSCLEROSIS; CELL FATE; CELL MIGRATION; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CONTRAST ENHANCEMENT; DRUG UPTAKE; HEART INFARCTION; HUMAN; IMAGE PROCESSING; MACROPHAGE; NEUTROPHIL; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SIGNAL DETECTION; ANIMAL; ARTERY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; INFLAMMATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CONTRAST MEDIA; DEXTRANS; HUMANS; INFLAMMATION; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; PARTICLE SIZE; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84941925930     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/s12968-015-0183-4     Document Type: Review

References (71)

1. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121:2437.
2. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation. 1995;92:1117-25.
3. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, et al. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Circ Cardiovasc Imaging. 2010;3:743-52.
4. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19:1599-605.
5. Schiller B, Bhat P, Sharma A, Li Z, Fortin G, McLaughlin J, et al. Safety of Feraheme®(Ferumoxytol) in hemodialysis patients at 3 dialysis chains over a 1-year period. J Am Soc Nephrol. 2011;22:477A-8.
6. Sharma A, Bhat P, Schiller B, Fortin G, McLaughlin J, Li Z, et al. Efficacy of Feraheme®(Ferumoxytol) administration on target hemoglobin levels and other iron parameters across 3 dialysis chains. J Am Soc Nephrol. 2011;22:485A.
7. Christen T, Ni W, Qiu D, Schmiedeskamp H, Bammer R, Moseley M, et al. High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol. Magn Reson Med. 2013; 70(3):705-10.
8. Saito S, Tsugeno M, Koto D, Mori Y, Yoshioka Y, Nohara S, et al. Impact of surface coating and particle size on the uptake of small and ultrasmall superparamagnetic iron oxide nanoparticles by macrophages. Int J Nanomedicine. 2012;7:5415-21.
9. Tsuchiya K, Nitta N, Sonoda A, Otani H, Takahashi M, Murata K, et al. Atherosclerotic imaging using 4 types of superparamagnetic iron oxides: new possibilities for mannan-coated particles. Eur J Radiol. 2013;82:1919-25.
10. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005;25:400-10.
11. Hunt MA, Bago AG, Neuwelt EA. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. AJNR Am J Neuroradiol. 2005;26:1084-8.
12. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415-22.
13. Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, Coussemacq M, et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med. 1999;41:329-33.
14. Gellissen J, Axmann C, Prescher A, Bohndorf K, Lodemann KP. Extra- and intracellular accumulation of ultrasmall superparamagnetic iron oxides (USPIO) in experimentally induced abscesses of the peripheral soft tissues and their effects on magnetic resonance imaging. Magn Reson Imaging. 1999;17:557-67.
15. Small WC, Nelson RC, Bernardino ME. Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide. Magn Reson Imaging. 1993;11:645-54.
16. Fananapazir G, Marin D, Suhocki PV, Kim CY, Bashir MR. Vascular artifact mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in abdominal vascular assessment. J Vasc Interv Radiol. 2014;25:969-76.
17. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol. 2000;35:460-71.
18. Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, et al. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol. 2002;37:405-11.
19. Sigovan M, Bessaad A, Alsaid H, Lancelot E, Corot C, Neyran B, et al. Assessment of age modulated vascular inflammation in ApoE-/- mice by USPIO-enhanced magnetic resonance imaging. Invest Radiol. 2010;45:702-7.
20. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, et al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol. 2006;26:176-81.
21. Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol. 2008;28:265-71.
22. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 1999;5:439-47.
23. Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, et al. Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther. 2002;301:15-20.
24. Brasier AR, Recinos A, 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-66.
25. Sigovan M, Kaye E, Lancelot E, Corot C, Provost N, Majd Z, et al. Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Invest Radiol. 2012;47:546-52.
26. Trivedi RA, Mallawarachi C, JM UK-I, Graves MJ, Horsley J, Goddard MJ, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26:1601-6.
27. Lutz AM, Weishaupt D, Persohn E, Goepfert K, Froehlich J, Sasse B, et al. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. Radiology. 2005;234:765-75.
28. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Li ZY, et al. Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced MR imaging with degree of luminal stenosis. Stroke. 2008;39:2144-7.
29. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
30. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-31.
31. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, JM UK-I, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53:2039-50.
32. Patterson AJ, Tang TY, Graves MJ, Muller KH, Gillard JH. In vivo carotid plaque MRI using quantitative T2∗measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy. NMR Biomed. 2011;24:89-95.
33. Sadat U, Taviani V, Patterson AJ, Young VE, Graves MJ, Teng Z, et al. Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of abdominal aortic aneurysms - a feasibility study. Eur J Vasc Endovasc Surg. 2011;41:167-74.
34. Howarth SP, Tang TY, Graves MJ, JM UK-I, Li ZY, Walsh SR, et al. Non-invasive MR imaging of inflammation in a patient with both asymptomatic carotid atheroma and an abdominal aortic aneurysm: a case report. Ann Surg Innov Res. 2007;1:4.
35. Richards JM, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging. 2011;4:274-81.
36. Braun JS, Jander S, Schroeter M, Witte OW, Stoll G. Spatiotemporal relationship of apoptotic cell death to lymphomonocytic infiltration in photochemically induced focal ischemia of the rat cerebral cortex. Acta Neuropathol. 1996;92:255-63.
37. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 2000;10:95-112.
38. Rausch M, Sauter A, Frohlich J, Neubacher U, Radu EW, Rudin M. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. Magn Reson Med. 2001;46:1018-22.
39. Wiart M, Davoust N, Pialat JB, Desestret V, Moucharrafie S, Cho TH, et al. MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke. 2007;38:131-7.
40. Desestret V, Brisset JC, Moucharrafie S, Devillard E, Nataf S, Honnorat J, et al. Early-stage investigations of ultrasmall superparamagnetic iron oxide-induced signal change after permanent middle cerebral artery occlusion in mice. Stroke. 2009;40:1834-41.
41. Yang YM, Feng X, Yin LK, Li CC, Jia J, Du ZG. Comparison of USPIO-enhanced MRI and Gd-DTPA enhancement during the subacute stage of focal cerebral ischemia in rats. Acta Radiol. 2014;55(7)864-73.
42. Yang YM, Feng XY, Yin le K, Li CC, Li AN, Jia J, et al. In vivo USPIO-enhanced MR signal characteristics of secondary degeneration in the ipsilateral substantia nigra after middle cerebral artery occlusion at 3 T. J Neuroradiol. 2013;40:198-203.
43. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain. 2004;127:1670-7.
44. Nighoghossian N, Wiart M, Cakmak S, Berthezene Y, Derex L, Cho TH, et al. Inflammatory response after ischemic stroke: a USPIO-enhanced MRI study in patients. Stroke. 2007;38:303-7.
45. Marinescu M, Chauveau F, Durand A, Riou A, Cho TH, Dencausse A, et al. Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced MRI. Eur Radiol. 2013;23(1):37-47.
46. Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5:559-65.
47. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88:3259-87.
48. Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ, et al. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology. 2006;241:469-76.
49. Segers FM, den Adel B, Bot I, van der Graaf LM, van der Veer EP, Gonzalez W, et al. Scavenger receptor-AI-targeted iron oxide nanoparticles for in vivo MRI detection of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2013;33:1812-9.
50. Riou A, Chauveau F, Cho TH, Marinescu M, Nataf S, Nighoghossian N, et al. MRI assessment of the intra-carotid route for macrophage delivery after transient cerebral ischemia. NMR Biomed. 2013;26(2):115-23.
51. Riviere C, Boudghene FP, Gazeau F, Roger J, Pons JN, Laissy JP, et al. Iron oxide nanoparticle-labeled rat smooth muscle cells: cardiac MR imaging for cell graft monitoring and quantitation. Radiology. 2005;235:959-67.
52. Nelson GN, Roh JD, Mirensky TL, Wang Y, Yi T, Tellides G, et al. Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo. FASEB J. 2008;22:3888-95.
53. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray TJ, et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans. Circ Cardiovasc Imaging. 2012; 5(4): 509-17.
54. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn Reson Med. 2005;53:329-38.
55. McAteer MA, von Zur Muhlen C, Anthony DC, Sibson NR, Choudhury RP. Magnetic resonance imaging of brain inflammation using microparticles of iron oxide. Methods Mol Biol. 2011;680:103-15.
56. Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med. 2010;63:33-40.
57. Boutry S, Brunin S, Mahieu I, Laurent S, Vander Elst L, Muller RN. Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study. Contrast Media Mol Imaging. 2008;3:223-32.
58. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular imaging techniques in body imaging. Radiology. 2007;245:333-56.
59. Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine. 2007;2:609-22.
60. Taupitz M, Wagner S, Schnorr J, Kravec I, Pilgrimm H, Bergmann-Fritsch H, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol. 2004;39:394-405.
61. Schnorr J, Taupitz M, Schellenberger EA, Warmuth C, Fahlenkamp UL, Wagner S, et al. Cardiac magnetic resonance angiography using blood-pool contrast agents: comparison of citrate-coated very small superparamagnetic iron oxide particles with gadofosveset trisodium in pigs. Rofo. 2012;184:105-12.
62. Wagner M, Wagner S, Schnorr J, Schellenberger E, Kivelitz D, Krug L, et al. Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging. 2011;34:816-23.
63. Ludwig A, Poller WC, Westphal K, Minkwitz S, Lattig-Tunnemann G, Metzkow S, et al. Rapid binding of electrostatically stabilized iron oxide nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans. Basic Res Cardiol. 2013;108:328.
64. Herborn CU, Vogt FM, Lauenstein TC, Dirsch O, Corot C, Robert P, et al. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging. 2006;24:388-93.
65. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453-8.
66. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Trivedi RA, et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study. J Neurol Neurosurg Psychiatry. 2007;78:1337-43.
67. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Li ZY, et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques in patients with asymptomatic carotid stenosis undergoing coronary artery bypass grafting: an ultrasmall superparamagnetic iron oxide enhanced magnetic resonance study. Eur J Vasc Endovasc Surg. 2008;35:392-8.
68. Rausch M, Baumann D, Neubacher U, Rudin M. In-vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO. NMR Biomed. 2002;15:278-83.
69. Krombach GA, Wendland MF, Higgins CB, Saeed M. MR imaging of spatial extent of microvascular injury in reperfused ischemically injured rat myocardium: value of blood pool ultrasmall superparamagnetic particles of iron oxide. Radiology. 2002;225:479-86.
70. Montet-Abou K, Daire JL, Hyacinthe JN, Jorge-Costa M, Grosdemange K, Mach F, et al. In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J. 2010;31:1410-20.
71. Kanno S, Wu YJ, Lee PC, Dodd SJ, Williams M, Griffith BP, et al. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation. 2001;104:934-8.